Siegel, R. L., Miller, Ok. D., Wagle, N. S. & Jemal, A. Most cancers statistics, 2023. CA Most cancers J. Clin. 73, 17–48 (2023).
Arnold, M. et al. Present and future burden of breast most cancers: world statistics for 2020 and 2040. Breast 66, 15–23 (2022).
Taylor, C. et al. Breast most cancers mortality in 500 000 girls with early invasive breast most cancers recognized in England, 1993-2015: inhabitants based mostly observational cohort examine. BMJ 381, e074684 (2023).
Caswell-Jin, J. L. et al. Change in survival in metastatic breast most cancers with remedy advances: meta-analysis and systematic evaluation. JNCI Most cancers Spectr. 2, pky062 (2018).
World Well being Group. International well being estimates 2020: deaths by trigger, age, intercourse, by nation and by area, 2000–2019 (WHO, 2020).
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast most cancers. Breast Most cancers Res. 12, R68 (2010).
Cortes, J. et al. Pembrolizumab plus chemotherapy in superior triple-negative breast most cancers. N. Engl. J. Med. 387, 217–226 (2022).
Swanton, C. et al. Embracing most cancers complexity: hallmarks of systemic illness. Cell 187, 1589–1616 (2024).
Engels, E. A. Epidemiologic views on immunosuppressed populations and the immunosurveillance and immunocontainment of most cancers. Am. J. Transpl. 19, 3223–3232 (2019).
Schmid, P. et al. Occasion-free survival with pembrolizumab in early triple-negative breast most cancers. N. Engl. J. Med. 386, 556–567 (2022). This section III trial demonstrates that concentrating on PD1 with pembrolizumab mixed with chemotherapy is simpler than chemotherapy alone in sufferers with early TNBC.
Schmid, P. et al. Pembrolizumab for early triple-negative breast most cancers. N. Engl. J. Med. 382, 810–821 (2020).
Mittendorf, E. A. et al. Neoadjuvant atezolizumab together with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in sufferers with early-stage triple-negative breast most cancers (IMpassion031): a randomised, double-blind, section 3 trial. Lancet 396, 1090–1100 (2020). This section III trial demonstrates that concentrating on PDL1 with atezolizumab mixed with chemotherapy is simpler than chemotherapy alone in sufferers with early TNBC.
Jackson, H. W. et al. The only-cell pathology panorama of breast most cancers. Nature 578, 615–620 (2020).
Loi, S. et al. Prognostic and predictive worth of tumor-infiltrating lymphocytes in a section III randomized adjuvant breast most cancers trial in node-positive breast most cancers evaluating the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860–867 (2013).
Danenberg, E. et al. Breast tumor microenvironment buildings are related to genomic options and scientific end result. Nat. Genet. 54, 660–669 (2022).
Pittet, M. J., Michielin, O. & Migliorini, D. Scientific relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 19, 402–421 (2022).
Costa, A. et al. Fibroblast heterogeneity and immunosuppressive surroundings in human breast most cancers. Most cancers Cell 33, 463–479.e10 (2018). This examine identifies 4 completely different subtypes of CAFs in breast most cancers and elucidates their function in regulating T cell perform by selling immune suppression.
Kieffer, Y. et al. Single-cell evaluation reveals fibroblast clusters linked to immunotherapy resistance in most cancers. Most cancers Discov. 10, 1330–1351 (2020).
Savas, P. et al. Single-cell profiling of breast most cancers T cells reveals a tissue-resident reminiscence subset related to improved prognosis. Nat. Med. 24, 986–993 (2018). This examine makes use of scRNA-seq to determine T cells with a tissue-resident memory-like phenotype in breast most cancers which can be related to an improved prognosis and means that these cells are key responders to ICB.
Salgado, R. et al. Tumor-infiltrating lymphocytes and associations with pathological full response and event-free survival in HER2-positive early-stage breast most cancers handled with lapatinib and trastuzumab: a secondary evaluation of the NeoALTTO trial. JAMA Oncol. 1, 448–454 (2015).
Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: a pooled particular person affected person evaluation of early-stage triple-negative breast cancers. J. Clin. Oncol. 37, 559–569 (2019).
Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in several subtypes of breast most cancers: a pooled evaluation of 3771 sufferers handled with neoadjuvant remedy. Lancet Oncol. 19, 40–50 (2018).
Loi, S. et al. Affiliation between biomarkers and scientific outcomes of pembrolizumab monotherapy in sufferers with metastatic triple-negative breast most cancers: KEYNOTE-086 exploratory evaluation. JCO Summary. Oncol. 7, e2200317 (2023).
Leon-Ferre, R. A. et al. Tumor-infiltrating lymphocytes in triple-negative breast most cancers. JAMA 331, 1135–1144 (2024).
Salgado, R. et al. The analysis of tumor-infiltrating lymphocytes (TILs) in breast most cancers: suggestions by an Worldwide TILs Working Group 2014. Ann. Oncol. 26, 259–271 (2015).
Cardoso, F. et al. Early breast most cancers: ESMO Scientific Follow Tips for prognosis, remedy and follow-up. Ann. Oncol. 30, 1194–1220 (2019).
Burstein, H. J. et al. Estimating the advantages of remedy for early-stage breast most cancers: the St. Gallen Worldwide Consensus Tips for the first remedy of early breast most cancers 2019. Ann. Oncol. 30, 1541–1557 (2019).
Luen, S., Virassamy, B., Savas, P., Salgado, R. & Loi, S. The genomic panorama of breast most cancers and its interplay with host immunity. Breast 29, 241–250 (2016).
Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast most cancers. Cell 177, 1330–1345.e18 (2019). This examine makes use of mass cytometry to analyse breast most cancers samples to offer a complete atlas of immune cell composition and phenotype within the TME and relationship with tumour cells.
Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 53, 1334–1347 (2021).
Keren, L. et al. A structured tumor-immune microenvironment in triple unfavorable breast most cancers revealed by multiplexed ion beam imaging. Cell 174, 1373–1387.e19 (2018). This examine makes use of multiplexed ion beam imaging by time-of-flight to analyse the immune microenvironment of TNBC samples, offering quantitative data and spatial data to disclose the group of the TME.
Ali, H. R. et al. Imaging mass cytometry and multiplatform genomics outline the phenogenomic panorama of breast most cancers. Nat. Most cancers 1, 163–175 (2020).
Desmedt, C. et al. Immune infiltration in invasive lobular breast most cancers. J. Natl Most cancers Inst. 110, 768–776 (2018).
Cepek, Ok. L. et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature 372, 190–193 (1994).
Tietscher, S. et al. A complete single-cell map of T cell exhaustion-associated immune environments in human breast most cancers. Nat. Commun. 14, 98 (2023).
Pal, B. et al. A single-cell RNA expression atlas of regular, preneoplastic and tumorigenic states within the human breast. Embo j. 40, e107333 (2021). This examine makes use of scRNA-seq to analyse the transcriptome of wholesome breast, pre-neoplastic and breast most cancers tissue, offering detailed decision of the mobile range in wholesome tissue to tumour.
Virassamy, B. et al. Intratumoral CD8+ T cells with a tissue-resident reminiscence phenotype mediate native immunity and immune checkpoint responses in breast most cancers. Most cancers Cell 41, 585–601.e588 (2023).
Wang, Z. Q. et al. CD103 and intratumoral immune response in breast most cancers. Clin. Most cancers Res. 22, 6290–6297 (2016).
Lee, Y. J. et al. CD39+ tissue-resident reminiscence CD8+ T cells with a clonal overlap throughout compartments mediate antitumor immunity in breast most cancers. Sci. Immunol. 7, eabn8390 (2022).
Mackay, L. Ok. et al. Leading edge: CD69 interference with sphingosine-1-phosphate receptor perform regulates peripheral T cell retention. J. Immunol. 194, 2059–2063 (2015).
Skon, C. N. et al. Transcriptional downregulation of S1pr1 is required for the institution of resident reminiscence CD8+ T cells. Nat. Immunol. 14, 1285–1293 (2013).
Allakhverdi, Z. et al. Expression of CD103 identifies human regulatory T-cell subsets. J. Allergy Clin. Immunol. 118, 1342–1349 (2006).
Shiow, L. R. et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440, 540–544 (2006).
Gavil, N. V. et al. Continual antigen in strong tumors drives a definite program of T cell residence. Sci. Immunol. 8, eadd5976 (2023).
Corgnac, S. et al. CD103+CD8+ TRM cells accumulate in tumors of anti-PD-1-responder lung most cancers sufferers and are tumor-reactive lymphocytes enriched with Tc17. Cell Rep. Med. 1, 100127 (2020).
Luoma, A. M. et al. Tissue-resident reminiscence and circulating T cells are early responders to pre-surgical most cancers immunotherapy. Cell 185, 2918–2935.e29 (2022).
Losurdo, A. et al. Single-cell profiling defines the prognostic good thing about CD39excessive tissue resident reminiscence CD8+ T cells in luminal-like breast most cancers. Commun. Biol. 4, 1117 (2021).
Simoni, Y. et al. Bystander CD8+ T cells are considerable and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
Canale, F. P. et al. CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells. Most cancers Res. 78, 115–128 (2018).
Bossio, S. N. et al. CD39+ standard CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and increase upon CTLA-4 blockade. Oncoimmunology 12, 2246319 (2023).
Weber, B. N. et al. A vital function for TCF-1 in T-lineage specification and differentiation. Nature 476, 63–68 (2011).
Raghu, D., Xue, H. H. & Mielke, L. A. Management of lymphocyte destiny, an infection, and tumor immunity by TCF-1. Tendencies Immunol. 40, 1149–1162 (2019).
Johnson, J. L. et al. Lineage-determining transcription issue TCF-1 initiates the epigenetic id of T cells. Immunity 48, 243–257.e10 (2018).
Wang, X. Q. et al. Spatial predictors of immunotherapy response in triple-negative breast most cancers. Nature 621, 868–876 (2023).
Bassez, A. et al. A single-cell map of intratumoral modifications throughout anti-PD1 remedy of sufferers with breast most cancers. Nat. Med. 27, 820–832 (2021). This examine identifies genes related to T cell growth post-treatment via single-cell profiling and T cell receptor sequencing of biopsies collected pre-anti-PD1 remedy and after anti-PD1 remedy.
Salgado, R. et al. How present assay approval insurance policies are resulting in unintended imprecision medication. Lancet Oncol. 21, 1399–1401 (2020).
Qin, Y. et al. Tumor-infiltrating B cells as a good prognostic biomarker in breast most cancers: a scientific evaluation and meta-analysis. Most cancers Cell Int. 21, 310 (2021).
Garaud, S. et al. Tumor infiltrating B-cells sign purposeful humoral immune responses in breast most cancers. JCI Perception 5, e129641 (2019).
Helmink, B. A. et al. B cells and tertiary lymphoid buildings promote immunotherapy response. Nature 577, 549–555 (2020).
Thacker, G. et al. Immature pure killer cells promote development of triple-negative breast most cancers. Sci. Transl. Med. 15, eabl4414 (2023).
Wang, Y. et al. Tissue-resident macrophages promote extracellular matrix homeostasis within the mammary gland stroma of nulliparous mice. eLife 9, e57438 (2020).
Dawson, C. A. et al. Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling. Nat. Cell Biol. 22, 546–558 (2020).
Plaks, V. et al. Adaptive immune regulation of mammary postnatal organogenesis. Dev. Cell 34, 493–504 (2015).
Azizi, E. et al. Single-cell map of various immune phenotypes within the breast tumor microenvironment. Cell 174, 1293–1308.e36 (2018). This examine concludes, via scRNA-seq and T cell receptor sequencing profiling of immune cells from breast tumours and matched, blood, lymph node and regular breast tissue, that T cells exist in a state of steady activation and that macrophages don’t exist in distinct states of polarization.
Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Most cancers Cell 35, 588–602.e10 (2019).
Onkar, S. et al. Immune panorama in invasive ductal and lobular breast most cancers reveals a divergent macrophage-driven microenvironment. Nat. Most cancers 4, 516–534 (2023).
Jaitin, D. A. et al. Lipid-associated macrophages management metabolic homeostasis in a Trem2-dependent method. Cell 178, 686–698.e14 (2019).
Nalio Ramos, R. et al. Tissue-resident FOLR2+ macrophages affiliate with CD8+ T cell infiltration in human breast most cancers. Cell 185, 1189–1207.e25 (2022). This examine identifies FOLR2+ tissue-resident macrophages in breast most cancers which work together with and prime T cells and are related to improved affected person survival.
Cansever, D. et al. Lactation-associated macrophages exist in murine mammary tissue and human milk. Nat. Immunol. 24, 1098–1109 (2023).
Molgora, M. et al. TREM2 modulation remodels the tumor myeloid panorama enhancing anti-PD-1 immunotherapy. Cell 182, 886–900.e17 (2020). This examine finds TREM2 expression to be inversely correlated with total survival in sufferers with TNBC and identifies TREM2 as a possible goal on tumour-associated macrophages to enhance responses to ICB.
Yofe, I. et al. Spatial and temporal mapping of breast most cancers lung metastases determine TREM2 macrophages as regulators of the metastatic boundary. Most cancers Discov. 13, 2610–2631 (2023).
Ulland, T. Ok. et al. TREM2 maintains microglial metabolic health in Alzheimer’s illness. Cell 170, 649–663.e13 (2017).
Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals uncommon activating antigen-presenting cells vital for T cell immunity. Most cancers Cell 26, 638–652 (2014).
Bense, R. D. et al. Relevance of tumor-infiltrating immune cell composition and performance for illness end result in breast most cancers. J. Natl Most cancers Inst. 109, djw192 (2017).
Ali, H. R., Chlon, L., Pharoah, P. D., Markowetz, F. & Caldas, C. Patterns of immune infiltration in breast most cancers and their scientific implications: a gene-expression-based retrospective examine. PLoS Med. 13, e1002194 (2016).
Majorini, M. T., Colombo, M. P. & Lecis, D. Few, however environment friendly: the function of mast cells in breast most cancers and different strong tumors. Most cancers Res. 82, 1439–1447 (2022).
Reddy, S. M. et al. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast most cancers. Most cancers Immunol. Res. 7, 1025–1035 (2019).
Cords, L. et al. Most cancers-associated fibroblast classification in single-cell and spatial proteomics information. Nat. Commun. 14, 4294 (2023).
Mayer, S. et al. The tumor microenvironment exhibits a hierarchy of cell-cell interactions dominated by fibroblasts. Nat. Commun. 14, 5810 (2023).
Wu, S. Z. et al. Stromal cell range related to immune evasion in human triple-negative breast most cancers. EMBO J. 39, e104063 (2020).
Pelon, F. et al. Most cancers-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast most cancers via complementary mechanisms. Nat. Commun. 11, 404 (2020).
Wu, Y. et al. FGFR blockade boosts T cell infiltration into triple-negative breast most cancers by regulating cancer-associated fibroblasts. Theranostics 12, 4564–4580 (2022).
Geldhof, V. et al. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in wholesome and malignant breast. Nat. Commun. 13, 5511 (2022).
Goveia, J. et al. An built-in gene expression panorama profiling strategy to determine lung tumor endothelial cell heterogeneity and angiogenic candidates. Most cancers Cell 37, 21–36.e13 (2020).
Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier selling tolerance in tumors. Nat. Med. 20, 607–615 (2014).
Asrir, A. et al. Tumor-associated excessive endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 mixture immunotherapy. Most cancers Cell 40, 318–334.e19 (2022).
Martinet, L. et al. Human strong tumors include excessive endothelial venules: affiliation with T- and B-lymphocyte infiltration and favorable prognosis in breast most cancers. Most cancers Res. 71, 5678–5687 (2011).
Chen, L. et al. Famitinib with camrelizumab and nab-paclitaxel for superior immunomodulatory triple-negative breast most cancers (FUTURE-C-Plus): an open-label, single-arm, section II trial. Clin. Most cancers Res. 28, 2807–2817 (2022).
Risom, T. et al. Transition to invasive breast most cancers is related to progressive modifications within the construction and composition of tumor stroma. Cell 185, 299–310.e18 (2022). This examine, utilizing multiplexed ion beam imaging by time-of-flight to match the TME of matched regular breast, DCIS and invasive breast most cancers samples, means that DCIS with elevated expression of E-cadherin and a steady myoepithelium are at elevated danger of recurrence.
Gil Del Alcazar, C. R. et al. Immune escape in breast most cancers throughout in situ to invasive carcinoma transition. Most cancers Discov. 7, 1098–1115 (2017).
Nachmanson, D. et al. The breast pre-cancer atlas illustrates the molecular and micro-environmental range of ductal carcinoma in situ. NPJ Breast Most cancers 8, 6 (2022).
Almekinders, M. M. et al. Complete multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment concerning subsequent ipsilateral invasive breast most cancers danger. Br. J. Most cancers 127, 1201–1213 (2022).
Strand, S. H. et al. Molecular classification and biomarkers of scientific end result in breast ductal carcinoma in situ: evaluation of TBCRC 038 and RAHBT cohorts. Most cancers Cell 40, 1521–1536.e27 (2022).
Szekely, B. et al. Immunological variations between main and metastatic breast most cancers. Ann. Oncol. 29, 2232–2239 (2018).
Cimino-Mathews, A. et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in main and metastatic breast carcinomas. Hum. Pathol. 47, 52–63 (2016).
Boman, C. et al. Discordance of PD-L1 standing between main and metastatic breast most cancers: a scientific evaluation and meta-analysis. Most cancers Deal with. Rev. 99, 102257 (2021).
Emens, L. A. et al. Atezolizumab and nab-paclitaxel in superior triple-negative breast most cancers: biomarker analysis of the IMpassion130 examine. J. Natl Most cancers Inst. 113, 1005–1016 (2021).
Bonneau, C. et al. A subset of activated fibroblasts is related to distant relapse in early luminal breast most cancers. Breast Most cancers Res. 22, 76 (2020).
Aftimos, P. et al. Genomic and transcriptomic analyses of breast most cancers primaries and matched metastases in AURORA, the Breast Worldwide Group (BIG) molecular screening initiative. Most cancers Discov. 11, 2796–2811 (2021).
Garcia-Recio, S. et al. Multiomics in main and metastatic breast tumors from the AURORA US community finds microenvironment and epigenetic drivers of metastasis. Nat. Most cancers 4, 128–147 (2023).
Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue mobile heterogeneity panorama. Genome Biol. 18, 220 (2017).
Schmid, P. et al. Atezolizumab and nab-paclitaxel in superior triple-negative breast most cancers. N. Engl. J. Med. 379, 2108–2121 (2018).
Adams, S. et al. Pembrolizumab monotherapy for beforehand handled metastatic triple-negative breast most cancers: cohort A of the section II KEYNOTE-086 examine. Ann. Oncol. 30, 397–404 (2019).
Brown, Ok. A. et al. Menopause is a determinant of breast aromatase expression and its associations with BMI, irritation, and systemic markers. J. Clin. Endocrinol. Metab. 102, 1692–1701 (2017).
Dunbier, A. Ok. et al. Relationship between plasma estradiol ranges and estrogen-responsive gene expression in estrogen receptor-positive breast most cancers in postmenopausal girls. J. Clin. Oncol. 28, 1161–1167 (2010).
Nanda, R. et al. Impact of pembrolizumab plus neoadjuvant chemotherapy on pathologic full response in girls with early-stage breast most cancers: an evaluation of the continued section 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6, 676–684 (2020).
Pusztai, L. et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast most cancers: outcomes from the adaptively randomized I-SPY2 trial. Most cancers Cell 39, 989–998.e5 (2021).
Voorwerk, L. et al. Immune panorama of breast tumors with low and intermediate estrogen receptor expression. NPJ Breast Most cancers 9, 39 (2023).
Loi, S. et al. LBA20 a randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) adopted by adjuvant endocrine remedy (ET) ± NIVO in sufferers (pts) with high-risk, ER+ HER2− main breast most cancers (BC). Ann. Oncol. 34, S1259–S1260 (2023).
Hanamura, T. et al. Expression of hormone receptors is related to particular immunological profiles of the breast most cancers microenvironment. Breast Most cancers Res. 25, 13 (2023).
Quigley, D. A. et al. Age, estrogen, and immune response in breast adenocarcinoma and adjoining regular tissue. Oncoimmunology 6, e1356142 (2017).
Oesterreich, S. et al. Estrogen-mediated down-regulation of E-cadherin in breast most cancers cells. Most cancers Res. 63, 5203–5208 (2003).
Rae, J. M. & Lippman, M. E. The function of estrogen receptor signaling in suppressing the immune response to most cancers. J. Clin. Make investments. 131, e155476 (2021).
Svoronos, N. et al. Tumor cell-independent estrogen signaling drives illness development via mobilization of myeloid-derived suppressor cells. Most cancers Discov. 7, 72–85 (2017).
Polanczyk, M. J. et al. Leading edge: estrogen drives growth of the CD4+CD25+ regulatory T cell compartment. J. Immunol. 173, 2227–2230 (2004).
Polanczyk, M. J., Hopke, C., Vandenbark, A. A. & Offner, H. Treg suppressive exercise entails estrogen-dependent expression of programmed death-1 (PD-1). Int. Immunol. 19, 337–343 (2007).
Hazlett, J. et al. Oestrogen deprivation induces chemokine manufacturing and immune cell recruitment in in vitro and in vivo fashions of oestrogen receptor-positive breast most cancers. Breast Most cancers Res. 23, 95 (2021).
Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated inhabitants burden of chosen autoimmune ailments in america. Clin. Immunol. Immunopathol. 84, 223–243 (1997).
Klein, S. L. & Flanagan, Ok. L. Intercourse variations in immune responses. Nat. Rev. Immunol. 16, 626–638 (2016).
Schafer, J. M. et al. Intercourse-biased adaptive immune regulation in most cancers improvement and remedy. iScience 25, 104717 (2022).
Ye, Y. et al. Intercourse-associated molecular variations for most cancers immunotherapy. Nat. Commun. 11, 1779 (2020).
Erlebacher, A. Mechanisms of T cell tolerance in direction of the allogeneic fetus. Nat. Rev. Immunol. 13, 23–33 (2013).
Ander, S. E., Diamond, M. S. & Coyne, C. B. Immune responses on the maternal-fetal interface. Sci. Immunol. 4, eaat6114 (2019).
Shao, C. et al. Prognosis of pregnancy-associated breast most cancers: a meta-analysis. BMC Most cancers 20, 746 (2020).
Thomas, R., Wang, W. & Su, D. M. Contributions of age-related thymic involution to immunosenescence and inflammaging. Immun. Ageing 17, 2 (2020).
Thompson, E. et al. The immune microenvironment of breast ductal carcinoma in situ. Mod. Pathol. 29, 249–258 (2016).
Marongiu, F. & DeGregori, J. The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related illness. Mol. Oncol. 16, 3238–3258 (2022).
Berben, L. et al. Age-related remodelling of the blood immunological portrait and the native tumor immune response in sufferers with luminal breast most cancers. Clin. Transl. Immunol. 9, e1184 (2020).
Qing, T. et al. Molecular variations between youthful versus older ER-positive and HER2-negative breast cancers. NPJ Breast Most cancers 8, 119 (2022).
Piccart, M. J. et al. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast most cancers: stronger proof, larger belief. Ann. Oncol. 32, 1077–1082 (2021).
Solar, H., Huang, W., Ji, F., Pan, Y. & Yang, L. Comparisons of metastatic patterns, survival outcomes and tumor immune microenvironment between younger and non-young breast most cancers sufferers. Entrance. Cell Dev. Biol. 10, 923371 (2022).
Sceneay, J. et al. Interferon signaling is diminished with age and is related to immune checkpoint blockade efficacy in triple-negative breast most cancers. Most cancers Discov. 9, 1208–1227 (2019).
Adams, S. et al. Pembrolizumab monotherapy for beforehand untreated, PD-L1-positive, metastatic triple-negative breast most cancers: cohort B of the section II KEYNOTE-086 examine. Ann. Oncol. 30, 405–411 (2019).
Garcia, M. G. et al. Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade most cancers immunotherapy efficacy in aged versus younger mice. Getting older Most cancers 3, 68–83 (2022).
Stephens, P. J. et al. The panorama of most cancers genes and mutational processes in breast most cancers. Nature 486, 400–404 (2012).
Shin, H. C. et al. Detection of germline mutations in breast most cancers sufferers with scientific options of hereditary most cancers syndrome utilizing a multi-gene panel check. Most cancers Res. Deal with. 52, 697–713 (2020).
Mak, T. W. et al. Brca1 required for T cell lineage improvement however not TCR loci rearrangement. Nat. Immunol. 1, 77–82 (2000).
Wu, B. et al. BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity. J. Immunother. Most cancers 11, e005852 (2023).
Jeong, J. H., Jo, A., Park, P., Lee, H. & Lee, H. O. Brca2 deficiency results in T cell loss and immune dysfunction. Mol. Cell 38, 251–258 (2015).
Barwell, J. et al. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast most cancers susceptibility. Int. J. Most cancers 121, 1631–1636 (2007).
Kote-Jarai, Z. et al. Elevated degree of chromosomal harm after irradiation of lymphocytes from BRCA1 mutation carriers. Br. J. Most cancers 94, 308–310 (2006).
Nolan, E. et al. Mixed immune checkpoint blockade as a therapeutic technique for BRCA1-mutated breast most cancers. Sci. Transl. Med. 9, eaal4922 (2017).
Solar, S. et al. Single-cell evaluation of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers. J. Clin. Make investments. 132, e148113 (2022).
Galluzzi, L., Kepp, O., Hett, E., Kroemer, G. & Marincola, F. M. Immunogenic cell demise in most cancers: idea and therapeutic implications. J. Transl. Med. 21, 162 (2023).
Ciampricotti, M., Hau, C.-S., Doornebal, C. W., Jonkers, J. & de Visser, Ok. E. Chemotherapy response of spontaneous mammary tumors is impartial of the adaptive immune system. Nat. Med. 18, 344–346 (2012).
Jacob, S. L., Huppert, L. A. & Rugo, H. S. Function of immunotherapy in breast most cancers. JCO Oncol. Pract. 19, 167–179 (2023).
Emens, L. A. et al. Lengthy-term scientific outcomes and biomarker analyses of atezolizumab remedy for sufferers with metastatic triple-negative breast most cancers: a section 1 examine. JAMA Oncol. 5, 74–82 (2019).
Emens, L. A. & Loi, S. Immunotherapy approaches for breast most cancers sufferers in 2023. Chilly Spring Harb. Perspect. Med. 13, a041332 (2023).
Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Therapy panorama of triple-negative breast most cancers — expanded choices, evolving wants. Nat. Rev. Clin. Oncol. 19, 91–113 (2022).
Emens, L. A. et al. 296P tumour mutational burden and scientific outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast most cancers: exploratory evaluation of the section III IMpassion130 trial. Ann. Oncol. 31, S360–S361 (2020).
Dixon-Douglas, J., Loibl, S., Denkert, C., Telli, M. & Loi, S. Integrating immunotherapy into the remedy panorama for sufferers with triple-negative breast most cancers. Am. Soc. Clin. Oncol. Educ. Ebook. 42, 1–13 (2022).
Shahbandi, A. et al. Breast most cancers cells survive chemotherapy by activating targetable immune-modulatory applications characterised by PD-L1 or CD80. Nat. Most cancers 3, 1513–1533 (2022).
Hodge, J. W. et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell demise. Int. J. Most cancers 133, 624–636 (2013).
Liu, W. M., Fowler, D. W., Smith, P. & Dalgleish, A. G. Pre-treatment with chemotherapy can improve the antigenicity and immunogenicity of tumours by selling adaptive immune responses. Br. J. Most cancers 102, 115–123 (2010).
Emens, L. A. et al. The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) exercise in metastatic triple-negative breast most cancers (mTNBC): IMpassion130. J. Clin. Oncol. 39, 1006 (2021).
Winship, A. L. et al. Checkpoint inhibitor immunotherapy diminishes oocyte quantity and high quality in mice. Nat. Most cancers 3, 1–13 (2022).
Loibl, S. et al. Neoadjuvant durvalumab improves survival in early triple-negative breast most cancers impartial of pathological full response. Ann. Oncol. 33, 1149–1158 (2022).
Liu, J. et al. Improved efficacy of neoadjuvant in comparison with adjuvant immunotherapy to eradicate metastatic illness. Most cancers Discov. 6, 1382–1399 (2016).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03498716 (2018).
Barrios, C. H. et al. Last evaluation of the placebo-controlled randomised section 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) adopted by open-label adjuvant atezo in sufferers (pts) with early-stage triple-negative breast most cancers (eTNBC). Annals Oncol. 8, abstr. LBA1, 101220-101220 (2023).
Ademuyiwa, F. O. et al. A randomized section 2 examine of neoadjuvant carboplatin and paclitaxel with or with out atezolizumab in triple unfavorable breast most cancers (TNBC) – NCI 10013. NPJ Breast Most cancers 8, 134 (2022).
Sharma, P. et al. Scientific and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast most cancers: NeoPACT section 2 scientific trial. JAMA Oncol. 10, 227–235 (2023).
Loi, S. et al. Randomized Part II Examine of Neoadjuvant Nivolumab (N) 2 week lead-in adopted by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Destructive Breast Most cancers (TNBC): (BCT1902/IBCSG 61-20 Neo-N). Most cancers Res. 84, abstr. LBO1–03, https://doi.org/10.1158/1538-7445.SABCS23-LBO1-03 (2024).
Cardoso, F. et al. LBA21 KEYNOTE-756: section III examine of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), adopted by adjuvant pembro or pbo + endocrine remedy (ET) for early-stage high-risk ER+/HER2− breast most cancers. Ann. Oncol. 34, S1260–S1261 (2023).
Dieci, M. V. et al. Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast most cancers: outcomes of the section II GIADA trial. Clin. Most cancers Res. 28, 308–317 (2022).
Rugo, H. S. et al. Security and antitumor exercise of pembrolizumab in sufferers with estrogen receptor-positive/human epidermal progress issue receptor 2-negative superior breast most cancers. Clin. Most cancers Res. 24, 2804–2811 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03725059 (2018).
Merck. Merck publicizes section 3 KEYNOTE-756 trial met main endpoint of pathological full response (pCR) charge in sufferers with high-risk, early-stage ER+/HER2- breast most cancers. Merck https://www.merck.com/information/merck-announces-phase-3-keynote-756-trial-met-primary-endpoint-of-pathological-complete-response-pcr-rate-in-patients-with-high-risk-early-stage-er-her2-breast-cancer/ (2023).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03879174 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://traditional.clinicaltrials.gov/ct2/present/NCT03393845 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://traditional.clinicaltrials.gov/ct2/present/NCT03874325 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03280563 (2017).
US Nationwide Library of Medication. ClinicalTrials.gov https://traditional.clinicaltrials.gov/ct2/present/NCT02778685 (2016).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT02779751 (2016).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03294694 (2017).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03573648 (2018).
Weigelt, B., Eberle, C., Cowell, C. F., Ng, C. Ok. & Reis-Filho, J. S. Metaplastic breast carcinoma: greater than a particular sort. Nat. Rev. Most cancers 14, 147–148 (2014).
Adams, S. et al. A multicenter section II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast most cancers: cohort 36 of twin anti-CTLA-4 and anti-PD-1 blockade in uncommon tumors (DART, SWOG S1609). Clin. Most cancers Res. 28, 271–278 (2022).
Roussos Torres, E. T. et al. Entinostat, nivolumab and ipilimumab for girls with superior HER2-negative breast most cancers: a section Ib trial. Nat. Most cancers https://doi.org/10.1038/s43018-024-00729-w (2024).
Loi, S. et al. Neoadjuvant ipilimumab and nivolumab together with paclitaxel following anthracycline-based chemotherapy in sufferers with remedy resistant early-stage triple-negative breast most cancers (TNBC): a single-arm section 2 trial. J. Clin. Oncol. 40, 602 (2022).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03726879 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT04873362 (2021).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT04348643 (2020).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03682744 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03696030 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03740256 (2020).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT04430595 (2020).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT04511871 (2020).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02792114 (2016).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02414269 (2015).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT04025216 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT04020575 (2020).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT04107142 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02706392 (2016).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02830724 (2017).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02541370 (2015).
Jung, I. Y. et al. Tissue-resident reminiscence CAR T cells with stem-like traits show enhanced efficacy towards strong and liquid tumors. Cell Rep. Med. 4, 101053 (2023).
Zacharakis, N. et al. Breast cancers are immunogenic: immunologic analyses and a section II pilot scientific trial utilizing mutation-reactive autologous lymphocytes. J. Clin. Oncol. 40, 1741–1754 (2022).
Ayoub, N. M., Jaradat, S. Ok., Al-Shami, Ok. M. & Alkhalifa, A. E. Concentrating on angiogenesis in breast most cancers: present proof and future views of novel anti-angiogenic approaches. Entrance. Pharmacol. 13, 838133 (2022).
Salgado, R. & Loi, S. What’s in a reputation? That which we name immune cells by every other identify would all odor as candy. Clin. Most cancers Res. 28, 2728–2729 (2022).
US Nationwide Library of Medication. ClinicalTrials.gov https://traditional.clinicaltrials.gov/ct2/present/NCT04739670 (2021).
Timperi, E. et al. Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast most cancers. Most cancers Res. 82, 3291–3306 (2022).
Home, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin. Most cancers Res. 26, 487–504 (2020).
Linde, N. et al. Macrophages orchestrate breast most cancers early dissemination and metastasis. Nat. Commun. 9, 21 (2018).
Lin, H. et al. Discovery of a cytokine and its receptor by purposeful screening of the extracellular proteome. Science 320, 807–811 (2008).
Autio, Ok. A. et al. Immunomodulatory exercise of a colony-stimulating factor-1 receptor inhibitor in sufferers with superior refractory breast or prostate most cancers: a section I examine. Clin. Most cancers Res. 26, 5609–5620 (2020).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03335540 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03431948 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02435680 (2015).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03742349 (2019).
Terranova-Barberio, M. et al. Exhausted T cell signature predicts immunotherapy response in ER-positive breast most cancers. Nat. Commun. 11, 3584 (2020).
Matsumoto, H. et al. Elevated CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast most cancers. Breast Most cancers Res. Deal with. 156, 237–247 (2016).
Ladoire, S. et al. T-bet expression in intratumoral lymphoid buildings after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br. J. Most cancers 105, 366–371 (2011).
Gu-Trantien, C. et al. CD4+ follicular helper T cell infiltration predicts breast most cancers survival. J. Clin. Make investments. 123, 2873–2892 (2013).
Plitas, G. et al. Regulatory T cells exhibit distinct options in human breast most cancers. Immunity 45, 1122–1134 (2016).
Alizadeh, D. et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell switch in breast most cancers. Most cancers Res. 74, 104–118 (2014).
Mattarollo, S. R. et al. Pivotal function of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Most cancers Res. 71, 4809–4820 (2011).
Voorwerk, L. et al. Immune induction methods in metastatic triple-negative breast most cancers to reinforce the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920–928 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02499367 (2015).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02819518 (2016).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03639948 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02883062 (2017).
Kodumudi, Ok. N. et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Most cancers Res. 16, 4583–4594 (2010).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03881878 (2019).
Ahn, H. Ok. et al. Response charge and security of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab routine for sufferers with ERBB2-positive stage II/III breast most cancers: the Neo-PATH section 2 nonrandomized scientific trial. JAMA Oncol. 8, 1271–1277 (2022).
Wanderley, C. W. et al. Paclitaxel reduces tumor progress by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent method. Most cancers Res. 78, 5891–5900 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02425891 (2015).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02685059 (2016).
Heylmann, D. et al. Human CD4+CD25+ regulatory T cells are delicate to low dose cyclophosphamide: implications for the immune response. PLoS ONE 8, e83384 (2013).
Zhao, J. et al. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is defined by diminished intracellular ATP ranges. Most cancers Res. 70, 4850–4858 (2010).
Dimeloe, S. et al. Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are extra prone to cyclophosphamide-induced apoptosis. Eur. J. Immunol. 44, 3614–3620 (2014).
Huober, J. et al. Atezolizumab with neoadjuvant anti-human epidermal progress issue receptor 2 remedy and chemotherapy in human epidermal progress issue receptor 2-positive early breast most cancers: main outcomes of the randomized section III IMpassion050 trial. J. Clin. Oncol. 40, 2946–2956 (2022).
Richards, J. O., Albers, A. J., Smith, T. S. & Tjoe, J. A. NK cell-mediated antibody-dependent mobile cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, however not HER2/neu-amplified, breast most cancers cells. Most cancers Immunol. Immunother. 65, 1325–1335 (2016).
Chan, M. S. et al. Modifications of tumor infiltrating lymphocyte subtypes earlier than and after neoadjuvant endocrine remedy in estrogen receptor-positive breast most cancers sufferers — an immunohistochemical examine of Cd8+ and Foxp3+ utilizing double immunostaining with correlation to the pathobiological response of the sufferers. Int. J. Biol. Markers 27, e295–e304 (2012).
Generali, D. et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast most cancers sufferers. Clin. Most cancers Res. 15, 1046–1051 (2009).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT04109066 (2019).
Goel, S. et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471–475 (2017).
Hurvitz, S. A. et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, section II neoadjuvant examine in HR+/HER2− breast most cancers. Clin. Most cancers Res. 26, 566–580 (2020).
Rugo, H. S. et al. Abemaciclib together with pembrolizumab for HR+, HER2− metastatic breast most cancers: section 1b examine. NPJ Breast Most cancers 8, 118 (2022).
Kaneda, M. M. et al. PI3Kγ is a molecular swap that controls immune suppression. Nature 539, 437–442 (2016).
De Henau, O. et al. Overcoming resistance to checkpoint blockade remedy by concentrating on PI3Kγ in myeloid cells. Nature 539, 443–447 (2016).
Sai, J. et al. PI3K inhibition reduces mammary tumor progress and facilitates antitumor immunity and anti-PD1 responses. Clin. Most cancers Res. 23, 3371–3384 (2017).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03961698 (2019).
Hatem, S. et al. Up to date efficacy, security and translational information from MARIO-3, a section II open-label examine evaluating a novel triplet mixture of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) remedy for regionally superior or metastatic triple-negative breast most cancers (TNBC). Most cancers Res. 82, abstr. P5-P16-02 (2022).
Marks, D. Ok. et al. Akt inhibition is related to favorable immune profile modifications inside the tumor microenvironment of hormone receptor optimistic, HER2 unfavorable breast most cancers. Entrance. Oncol. 10, 968 (2020).
Bullock, Ok. Ok. et al. Endogenous pAKT exercise is related to response to AKT inhibition alone and together with immune checkpoint inhibition in murine fashions of TNBC. Most cancers Lett. 586, 216681 (2024).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03800836 (2018).
Schmid, P. et al. First-line ipatasertib, atezolizumab, and taxane triplet for metastatic triple-negative breast most cancers: scientific and biomarker outcomes. Clin. Most cancers Res. 30, 767–778 (2024).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT03337724 (2018).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/examine/NCT04177108 (2019).
Mehta, A. Ok. et al. Concentrating on immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast most cancers. Nat. Most cancers 2, 66–82 (2021).
Wang, L. et al. PARP-inhibition reprograms macrophages towards an anti-tumor phenotype. Cell Rep. 41, 111462 (2022).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02734004 (2016).
Domchek, S. M. et al. Olaparib and durvalumab in sufferers with germline BRCA-mutated metastatic breast most cancers (MEDIOLA): an open-label, multicentre, section 1/2, basket examine. Lancet Oncol. 21, 1155–1164 (2020).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT01042379 (2010).
Wang, Z. et al. Niraparib prompts interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor fashions. Sci. Rep. 9, 1853 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02657889 (2016).
Vinayak, S. et al. Open-label scientific trial of niraparib mixed with pembrolizumab for remedy of superior or metastatic triple-negative breast most cancers. JAMA Oncol. 5, 1132–1140 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03330405 (2017).
Yap, T. A. et al. Avelumab plus talazoparib in sufferers with superior strong tumors: the JAVELIN PARP Medley nonrandomized managed trial. JAMA Oncol. 9, 40–50 (2023).
Iwata, T. N., Sugihara, Ok., Wada, T. & Agatsuma, T. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse mannequin. PLoS ONE 14, e0222280 (2019).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03523572 (2018).
Hamilton, E. et al. Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in sufferers with HER2-expressing, superior breast most cancers: a 2-part, section 1b, multicenter, open-label examine. Most cancers Res. 81, abstr. PD3-07, https://doi.org/10.1158/1538-7445.SABCS20-PD3-07 (2021).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03742102 (2018).
Schmid, P. et al. PD11-08 trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) remedy for unresectable regionally superior/metastatic hormone receptor-negative (HR−), HER2-low breast most cancers: up to date outcomes from BEGONIA, a section 1b/2 examine. Most cancers Res. 83, abstr. PD11-08 (2023).
Müller, P. et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast most cancers extremely prone to CTLA-4/PD-1 blockade. Sci. Transl. Med. 7, 315ra188 (2015).
Hamilton, E. P. et al. Affect of anti-HER2 remedies mixed with atezolizumab on the tumor immune microenvironment in early or metastatic breast most cancers: outcomes from a section Ib examine. Clin. Breast Most cancers 21, 539–551 (2021).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02924883 (2016).
Emens, L. A. et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in beforehand handled, HER2-positive superior breast most cancers (KATE2): a section 2, multicentre, randomised, double-blind trial. Lancet Oncol. 21, 1283–1295 (2020).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT02605915 (2015).
US Nationwide Library of Medication. ClinicalTrials.gov https://www.clinicaltrials.gov/examine/NCT03032107 (2017).
Waks, A. G. et al. Part Ib examine of pembrolizumab together with trastuzumab emtansine for metastatic HER2-positive breast most cancers. J. Immunother. Most cancers 10, e005119 (2022).
Schmid, P. et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) remedy for unresectable regionally superior/metastatic triple-negative breast most cancers (a/mTNBC): up to date outcomes from BEGONIA, a section Ib/II examine. Ann. Oncol. 34, S337, abstr. 379MO (2023).
Hammond, M. E. et al. American Society of Scientific Oncology/School of American Pathologists guideline suggestions for immunohistochemical testing of estrogen and progesterone receptors in breast most cancers. J. Clin. Oncol. 28, 2784–2795 (2010).
Fu, N. Y. et al. Identification of quiescent and spatially restricted mammary stem cells which can be hormone responsive. Nat. Cell Biol. 19, 164–176 (2017).
Lim, E. et al. Aberrant luminal progenitors because the candidate goal inhabitants for basal tumor improvement in BRCA1 mutation carriers. Nat. Med. 15, 907–913 (2009).
Hu, L. et al. Single-Cell RNA sequencing reveals the mobile origin and evolution of breast most cancers in BRCA1 mutation carriers. Most cancers Res. 81, 2600–2611 (2021).
Nguyen, Q. H. et al. Profiling human breast epithelial cells utilizing single cell RNA sequencing identifies cell range. Nat. Commun. 9, 2028 (2018).
Ding, Y. et al. Cell lineage tracing hyperlinks ERα loss in Erbb2-positive breast cancers to the arising of a extremely aggressive breast most cancers subtype. Proc. Natl Acad. Sci. USA 118, e2100673118 (2021).
McCart Reed, A. E., Kutasovic, J. R., Lakhani, S. R. & Simpson, P. T. Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics. Breast Most cancers Res. 17, 12 (2015).
Arpino, G., Bardou, V. J., Clark, G. M. & Elledge, R. M. Infiltrating lobular carcinoma of the breast: tumor traits and scientific end result. Breast Most cancers Res. 6, R149–R156 (2004).
Casasent, A. Ok. et al. Studying to tell apart progressive and non-progressive ductal carcinoma in situ. Nat. Rev. Most cancers 22, 663–678 (2022).
Siracusa, F., Tintelnot, J., Cortesi, F. & Gagliani, N. Weight loss plan and immune response: how as we speak’s plate shapes tomorrow’s well being. Tendencies Immunol. 45, 4–10 (2023).
McIntyre, C. L., Temesgen, A. & Lynch, L. Weight loss plan, nutrient provide, and tumor immune responses. Tendencies Most cancers 9, 752–763 (2023).
Swaby, A., Atallah, A., Varol, O., Cristea, A. & Quail, D. F. Life-style and host determinants of antitumor immunity and most cancers well being disparities. Tendencies Most cancers 9, 1019–1040 (2023).
Koivula, T. et al. The impact of acute train on circulating immune cells in newly recognized breast most cancers sufferers. Sci. Rep. 13, 6561 (2023).
Bruinsma, T. J., Dyer, A.-M., Rogers, C. J., Schmitz, Ok. H. & Sturgeon, Ok. M. Results of weight-reduction plan and exercise-induced weight reduction on biomarkers of irritation in breast most cancers survivors: a scientific evaluation and meta-analysis. Most cancers Epidemiol. Biomark. Prev. 30, 1048–1062 (2021).
Devi, S. et al. Adrenergic regulation of the vasculature impairs leukocyte interstitial migration and suppresses immune responses. Immunity 54, 1219–1230.e17 (2021).
Hiller, J. G. et al. Preoperative β-blockade with propranolol reduces biomarkers of metastasis in breast most cancers: a section II randomized trial. Clin. Most cancers Res. 26, 1803–1811 (2020).
Pan, J. W. et al. The molecular panorama of Asian breast cancers reveals clinically related population-specific variations. Nat. Commun. 11, 6433 (2020).
Roy, A. M. et al. Racial and ethnic disparity in preoperative chemosensitivity and survival in sufferers with early-stage breast most cancers. JAMA Netw. Open 6, e2344517 (2023).
Shubeck, S., Zhao, F., Howard, F. M., Olopade, O. I. & Huo, D. Response to remedy, racial and ethnic disparity, and survival in sufferers with breast most cancers present process neoadjuvant chemotherapy within the US. JAMA Netw. Open 6, e235834 (2023).
Beral, V. et al. Collaborative group on hormonal components in breast most cancers and breastfeeding: collaborative reanalysis of particular person information from 47 epidemiological research in 30 nations, together with 50302 girls with breast most cancers and 96973 girls with out the illness. Lancet 360, 187–195 (2002).
El Tekle, G. & Garrett, W. S. Micro organism in most cancers initiation, promotion and development. Nat. Rev. Most cancers 23, 600–618 (2023).
Thompson, P. A. et al. Environmental immune disruptors, irritation and most cancers danger. Carcinogenesis 36, S232–S253 (2015).
Hoffmann, J. P., Liu, J. A., Seddu, Ok. & Klein, S. L. Intercourse hormone signaling and regulation of immune perform. Immunity 56, 2472–2491 (2023).
Passarelli, M. N. et al. Cigarette smoking earlier than and after breast most cancers prognosis: mortality from breast most cancers and smoking-related ailments. J. Clin. Oncol. 34, 1315–1322 (2016).
Tyagi, A. et al. Nicotine promotes breast most cancers metastasis by stimulating N2 neutrophils and producing pre-metastatic area of interest in lung. Nat. Commun. 12, 474 (2021).
Liu, Y. et al. Dysregulation of immunity by cigarette smoking promotes irritation and most cancers: a evaluation. Environ. Pollut. 339, 122730 (2023).
McQuade, J. L. et al. Affiliation of body-mass index and outcomes in sufferers with metastatic melanoma handled with focused remedy, immunotherapy, or chemotherapy: a retrospective, multicohort evaluation. Lancet Oncol. 19, 310–322 (2018).
Garbarino, S., Lanteri, P., Bragazzi, N. L., Magnavita, N. & Scoditti, E. Function of sleep deprivation in immune-related illness danger and outcomes. Commun. Biol. 4, 1304 (2021).
IARC Monographs Vol 124 group. Carcinogenicity of night time shift work. Lancet Oncol. 20, 1058–1059 (2019).
McDonald, Ok. A. et al. Tumor heterogeneity correlates with much less immune response and worse survival in breast most cancers sufferers. Ann. Surg. Oncol. 26, 2191–2199 (2019).
Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in most cancers development and response to immunotherapy. Nat. Med. 27, 212–224 (2021).
Yndestad, S. et al. Homologous recombination deficiency throughout subtypes of main breast most cancers. JCO Summary. Oncol. 7, e2300338 (2023).
Budczies, J. et al. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically chilly tumors in most most cancers varieties. J. Pathol. Clin. Res. 8, 371–382 (2022).
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy throughout a number of most cancers varieties. Nat. Genet. 51, 202–206 (2019).
Marabelle, A. et al. Affiliation of tumour mutational burden with outcomes in sufferers with superior strong tumours handled with pembrolizumab: potential biomarker evaluation of the multicohort, open-label, section 2 KEYNOTE-158 examine. Lancet Oncol. 21, 1353–1365 (2020).
Winer, E. P. et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast most cancers (KEYNOTE-119): a randomised, open-label, section 3 trial. Lancet Oncol. 22, 499–511 (2021).
Barroso-Sousa, R. et al. Prevalence and mutational determinants of excessive tumor mutation burden in breast most cancers. Ann. Oncol. 31, 387–394 (2020).
Karn, T. et al. Tumor mutational burden and immune infiltration as impartial predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann. Oncol. 31, 1216–1222 (2020).
Emami Nejad, A. et al. The function of hypoxia within the tumor microenvironment and improvement of most cancers stem cell: a novel strategy to growing remedy. Most cancers Cell Int. 21, 62 (2021).
Noer, J. B., Hørsdal, O. Ok., Xiang, X., Luo, Y. & Regenberg, B. Extrachromosomal round DNA in most cancers: historical past, present data, and strategies. Tendencies Genet. 38, 766–781 (2022).
Wu, S., Bafna, V., Chang, H. Y. & Mischel, P. S. Extrachromosomal DNA: an rising hallmark in human most cancers. Annu. Rev. Pathol. 17, 367–386 (2022).
Sade-Feldman, M. et al. Resistance to checkpoint blockade remedy via inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).
Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for beforehand untreated regionally recurrent inoperable or metastatic triple-negative breast most cancers (KEYNOTE-355): a randomised, placebo-controlled, double-blind, section 3 scientific trial. Lancet 396, 1817–1828 (2020).
Sompuram, S. R., Torlakovic, E. E., t Hart, N. A., Vani, Ok. & Bogen, S. A. Quantitative comparability of PD-L1 IHC assays towards NIST normal reference materials 1934. Mod. Pathol. 35, 326–332 (2022).
Islami, F. et al. Breastfeeding and breast most cancers danger by receptor status-a systematic evaluation and meta-analysis. Ann. Oncol. 26, 2398–2407 (2015).
Johansson, A. L. V. & Stensheim, H. Epidemiology of pregnancy-associated breast most cancers. Adv. Exp. Med. Biol. 1252, 75–79 (2020).
Hartman, E. Ok. & Eslick, G. D. The prognosis of girls recognized with breast most cancers earlier than, throughout and after being pregnant: a meta-analysis. Breast Most cancers Res. Deal with. 160, 347–360 (2016).
Pilewskie, M. et al. Affiliation between recency of final being pregnant and biologic subtype of breast most cancers. Ann. Surg. Oncol. 19, 1167–1173 (2012).
Sajjadi, E. et al. Breast most cancers throughout being pregnant as a particular sort of early-onset breast most cancers: evaluation of the tumor immune microenvironment and danger profiles. Cells 11, 2286 (2022).
Johansson, A. L. V. et al. Tumor traits and prognosis in girls with pregnancy-associated breast most cancers. Int. J. Most cancers 142, 1343–1354 (2018).
Schedin, P., O’Brien, J., Rudolph, M., Stein, T. & Borges, V. Microenvironment of the involuting mammary gland mediates mammary most cancers development. J. Mammary Gland Biol. Neoplasia 12, 71–82 (2007).
Martinson, H. A., Jindal, S., Durand-Rougely, C., Borges, V. F. & Schedin, P. Wound healing-like immune program facilitates postpartum mammary gland involution and tumor development. Int. J. Most cancers 136, 1803–1813 (2015).
Jindal, S. et al. Postpartum breast most cancers has a definite molecular profile that predicts poor outcomes. Nat. Commun. 12, 6341 (2021).
Azim, H. A. Jr. et al. Tumour infiltrating lymphocytes (TILs) in breast most cancers throughout being pregnant. Breast 24, 290–293 (2015).
